Literature DB >> 30104171

Hypersensitivity Reactions to Antiepileptic Drugs in Children: Epidemiologic, Pathogenetic, Clinical, and Diagnostic Aspects.

Semanur Kuyucu1, Jean-Christoph Caubet2.   

Abstract

Epilepsy affects approximately 10 million children globally. Antiepileptic drugs (AEDs) are among the most frequent causes of drug hypersensitivity reactions (DHRs), especially severe ones. However, systematic studies about AED hypersensitivity among children are very rare. In this review, we aimed to gather all relevant and important data about different aspects of DHRs to AEDs in children by conducting a PubMed search including English-language studies published between January 1990 and June 2017. In these studies, aromatic AEDs were mostly incriminated in DHRs, but still being dominantly prescribed in both developed and developing countries. Although newer AEDs were increasingly prescribed owing to their presumed low toxicity profile, surveillance of DHRs is strongly recommended because case reports about severe reactions were recently reported. The pathogenesis seemed to be multifactorial including metabolic, genetic, and immunologic factors. Recent pharmacogenomic studies demonstrated strong genetic associations between some human leucocyte antigens and/or polymorphisms of AED metabolic enzymes and AED-induced DHRs among both adults and children. Young children, concurrent medications, a high starting dose and rapid dose escalation, and some genetic markers are important risk factors for AED-induced hypersensitivity. There were a very limited number of studies in the pediatric population evaluating the efficacy of different available diagnostic tools, such as intradermal, patch, and drug provocation tests. Data including mostly adult patients showed that patch tests had relatively high diagnostic value to identify the culprit with a positivity rate that ranged between 19.7% and 100% in delayed reactions to AEDs. Clinical cross-reactivity rates of 15% to 70% have been reported mainly between aromatic AEDs. In selected cases, where there is no other option, desensitization can be considered, although experience in children remained limited.
Copyright © 2018 American Academy of Allergy, Asthma & Immunology. All rights reserved.

Entities:  

Keywords:  Antiepileptic drug; Aromatic antiepileptic; Desensitization; Drug allergy; Drug hypersensitivity; HLA; Patch test; Pharmacogenomics; Skin test

Mesh:

Substances:

Year:  2018        PMID: 30104171     DOI: 10.1016/j.jaip.2018.07.003

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  3 in total

1.  Slow graded reintroduction of oxcarbazepine for delayed maculopapular eruption.

Authors:  Christine R F Rukasin; Elizabeth J Phillips; Allison E Norton
Journal:  Ann Allergy Asthma Immunol       Date:  2019-06-12       Impact factor: 6.347

2.  Patterns of Antiepileptic Drug Reactions in Children: A Multicenter Study.

Authors:  Parinaz Sedighi; Neda Khalili; Nastaran Khalili; Amin Doosti-Irani; Atefeh Moradi; Samira Moghadam; Meshkat Nemati; Sobhan Mohammadi Jorjafki; Reza Shervin Badv; Iraj Sedighi
Journal:  Iran J Child Neurol       Date:  2022-07-16

3.  Emergent high fatality lung disease in systemic juvenile arthritis.

Authors:  Gail H Deutsch; R Paul Guillerman; Johannes Birgmeier; Karthik Jagadeesh; Scott Canna; Grant Schulert; Vivian E Saper; Guangbo Chen; Robin Deterding; Jianpeng Xu; Ann N Leung; Layla Bouzoubaa; Khalid Abulaban; Kevin Baszis; Edward M Behrens; James Birmingham; Alicia Casey; Michal Cidon; Randy Q Cron; Aliva De; Fabrizio De Benedetti; Ian Ferguson; Martha P Fishman; Steven I Goodman; T Brent Graham; Alexei A Grom; Kathleen Haines; Melissa Hazen; Lauren A Henderson; Assunta Ho; Maria Ibarra; Christi J Inman; Rita Jerath; Khulood Khawaja; Daniel J Kingsbury; Marisa Klein-Gitelman; Khanh Lai; Sivia Lapidus; Clara Lin; Jenny Lin; Deborah R Liptzin; Diana Milojevic; Joy Mombourquette; Karen Onel; Seza Ozen; Maria Perez; Kathryn Phillippi; Sampath Prahalad; Suhas Radhakrishna; Adam Reinhardt; Mona Riskalla; Natalie Rosenwasser; Johannes Roth; Rayfel Schneider; Dieneke Schonenberg-Meinema; Susan Shenoi; Judith A Smith; Hafize Emine Sönmez; Matthew L Stoll; Christopher Towe; Sara O Vargas; Richard K Vehe; Lisa R Young; Jacqueline Yang; Tushar Desai; Raymond Balise; Ying Lu; Lu Tian; Gill Bejerano; Mark M Davis; Purvesh Khatri; Elizabeth D Mellins
Journal:  Ann Rheum Dis       Date:  2019-09-27       Impact factor: 19.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.